Cartesian Therapeutics (RNAC) Profit After Tax (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Profit After Tax data on file, last reported at -$39.2 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 121.24% year-over-year to -$39.2 million in Q1 2026; TTM through Mar 2026 was -$151.8 million, a 296.17% decrease from a year earlier, with the FY2025 full-year figure at -$130.3 million, down 68.3% from the prior year.
• Profit After Tax for Q1 2026 stood at -$39.2 million, up from -$92.6 million in the prior quarter.
• Over the last five years, Profit After Tax for RNAC reached as high as $28.8 million in Q1 2022 and fell as low as -$177.7 million in Q4 2023.
• Historically, Profit After Tax has averaged -$25.4 million across 5 years, with a median of -$11.4 million in 2023.
• Across the five-year window, Profit After Tax plunged 3110.64% in 2023 and soared 221.51% in 2024, its largest moves.
• Year by year, Profit After Tax stood at $5.9 million in 2022, then plunged by 3110.64% to -$177.7 million in 2023, then jumped by 94.23% to -$10.2 million in 2024, then slumped by 803.78% to -$92.6 million in 2025, then soared by 57.69% to -$39.2 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$39.2 million in Q1 2026, -$92.6 million in Q4 2025, and -$35.9 million in Q3 2025.